Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT00875771 Completed - Clinical trials for Metastatic Colorectal Cancer

Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients

AVAXIRI
Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.

NCT ID: NCT00873756 Completed - Clinical trials for Metastatic Colorectal Cancer

A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Start date: May 2009
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label study enrolling a total of up to 23 patients.

NCT ID: NCT00865709 Completed - Clinical trials for Metastatic Colorectal Cancer

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Start date: March 2009
Phase: Phase 2
Study type: Interventional

To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.

NCT ID: NCT00862342 Completed - Clinical trials for Metastatic Colorectal Cancer

Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)

SAFE
Start date: January 2009
Phase: Phase 2
Study type: Interventional

Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy. A total of 1,953 patients were treated in BRiTE. At median follow-up of 17.5 mo, there were 1,369 1st PD and 839 deaths. Among patients with 1st PD, 65.2% received any 2nd-line chemotherapy, 34.8% received cetuximab, and 53.8% received BBP. In a multivariate analysis, Bevacizumab beyond first progression and exposure to any 2nd-line chemotherapy were independently associated with increased overall survival (both p < 0.0001). Bevacizumab beyond progression appears to be associated with longer overall in BRiTE. The investigators planned a prospective study to prove this phenomenon of bevacizumab beyond progression.

NCT ID: NCT00853931 Completed - Clinical trials for Metastatic Colorectal Cancer

Biomarker - Panitumumab Response With KRAS Wild Type MCC

Start date: October 2009
Phase: N/A
Study type: Interventional

This is an exploratory study in which all eligible subjects are given Panitumumab according to the dose and schedule approved by Health Canada. The purpose of this research study is to determine whether the presence of certain biomarkers (substances measurable in blood, normal cells or tumour tissue) are associated with an increased or decreased chance of benefit from panitumumab.

NCT ID: NCT00851136 Completed - Clinical trials for Metastatic Colorectal Cancer

A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)

Start date: May 2009
Phase: Phase 1
Study type: Interventional

This will be a multicenter, open-label study enrolling a total of up to 23 patients.

NCT ID: NCT00844233 Completed - Clinical trials for Metastatic Colorectal Cancer

Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer

PARAGON-II
Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in the neoadjuvant treatment (i.e. the Irinotecan Bead is administered prior to surgery) of resectable liver metastases from colorectal cancer.

NCT ID: NCT00835185 Completed - Clinical trials for Metastatic Colorectal Cancer

Study of IMC-11F8 in Participants With Colorectal Cancer

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).

NCT ID: NCT00827684 Completed - Clinical trials for Metastatic Colorectal Cancer

Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

TIRASMUS
Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of temsirolimus as a single drug, and of temsirolimus in combination with irinotecan in chemotherapy resistant patients with KRAS mutated colorectal cancer.

NCT ID: NCT00819780 Completed - Colorectal Cancer Clinical Trials

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Start date: April 24, 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.